We thank Dr Meis for the clarification and agree that the 17P in that trial was manufactured by a research pharmacy using the US Food and Drug Administration’s Good Manufacturing Practices.
References
- 1. Meis P.J., Klebanoff M., Thom E., et al: Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003; 348: pp. 2379-2385
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
